SGS Introduces New Specialized Bioanalytical Testing Services in North America

August 21, 2024 02:57 PM BST | By EIN Presswire
 SGS Introduces New Specialized Bioanalytical Testing Services in North America
Image source: EIN Presswire
EAST SUSSEX, UNITED KINGDOM, August 21, 2024 /EINPresswire.com/ -- SGS, the world’s leading testing, inspection and certification company, announces the introduction of new specialized bioanalytical testing services in the North American pharmaceutical and biopharmaceutical markets.

Delivered out of its state-of-the-art laboratory in Hudson, New Hampshire, close to the Boston Massachusetts Biotech Hub, SGS now offers comprehensive bioanalytical solutions to support discovery, pre-clinical and phase 1-3 clinical trials, including method transfer, development, validation, PD bioanalysis, PK bioanalysis, immunogenicity testing, ELISA and multiplex assays, bioassays and more.

These new service capabilities leverage SGS’s global partnership with Australian bioanalytical testing specialists, Agilex Biolabs. The addition of the Hudson lab expands the SGS global footprint, with bioanalytical labs already sited in France, Belgium, Switzerland, Germany and Shanghai. These locations all have harmonized regulatory systems and follow SGS global quality standards.

Derick Govender, Head of North America, SGS, commented on the expansion: “This is an exciting development for SGS, as we continue to expand our service offering to US and international markets. The introduction of this new specialized capability allows us to provide seamless bioanalytical testing services across phase 1 to phase 3 of the pre-clinical and clinical drug development process.”

With over 30 years of experience in the pharmaceutical industry, SGS offers comprehensive quality control testing for raw materials, APIs and finished products to support small and large molecule drug products. The new services offered at the Hudson facility complete SGS’s network of bioanalytical service centers, enabling global support for clinical trials.

Operating 20 laboratories in 11 countries, all fully compliant with the highest regulatory standards, SGS is the number one choice for manufacturers and developers engaged in the pharmaceutical and biopharmaceutical industries.

About SGS
We are SGS – the world’s leading testing, inspection and certification company. We are recognized as the global benchmark for sustainability, quality and integrity. Our 99,600 employees operate a network of 2,600 offices and laboratories around the world.​​​​​​​

For further information, please contact:

Jackie Brown
PR Account Executive, Sugarloaf Marketing Ltd
+44 7792970919
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next